

List of Publications

Dr. Neerja Bhatla

1. Muwonge R, Basu P, Gheit T, Anantharaman D, Verma Y, **Bhatla N**, Joshi S, Esmy PO; et al Indian HPV vaccine study group. Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort study. *PLOS One*, 2020 Dec;15(12):e0244242.
2. **Bhatla N**, Nessa A, Oswal K, Vashist S, Sebastian P, Basu P. Program organization rather than choice of test determines success of cervical cancer screening: Case studies from Bangladesh and India. *Int J Gynaecol Obstet*. 2021 Jan;152(1):40-47.
3. Boddu A, **Bhatla N**, Vashist S, Mathur S, Mahey R, Natarajan J, Malik R, Vanamail P, Rai S, Kumari A, Dar L, Wig N. Cervical cancer screening in HIV-positive women in India - Why, when and how? *J ObstetGynaecol India*, May-June 2021;71(3):304–312.
4. Kehoe S, **Bhatla N**; FIGO Gynecologic Oncology Committee. FIGO stage IIB cervical cancer prognostication in low-resource settings. *Int J Gynecol Obstet*. 2020 May;149(2):254.
5. Basu P, Malvi SG, Joshi S, **Bhatla N**, Muwonge R, Lucas E, Verma Y, Esmy PO, Poli UR, Shah A, Zomawia E. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. *The Lancet Oncology*. 2021 Nov 1;22(11):1518-29.
6. **Bhatla N**, Berek JS, CuelloFredes M, Denny LA, Grenman S, Karunaratne K, Kehoe ST, Konishi I, Olawaiye AB, Prat J, Sankaranarayanan R. Revised FIGO staging for carcinoma of the cervix uteri. *International Journal of Gynecology& Obstetrics*. 2019 Apr;145(1):129-35.
7. Joshi S, Anantharaman D, Muwonge R, **Bhatla N**, Panicker G, Butt J, Poli UR, Malvi SG, Esmy PO, Lucas E, Verma Y. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. *Vaccine*. 2023 Jan 4;41(1):236-45.
8. Broutet N, Jeronimo J, Kumar S, Almonte M, Murillo R, Huy NV, Denny L, Kapambwe S, **Bhatla N**, Sebitloane M, Zhao F. Implementation research to accelerate

scale-up of national screen and treat strategies towards the elimination of cervical cancer. *Preventive Medicine*. 2022 Feb 1;155:106906.

9. Garland SM, Anagani M, **Bhatla N**, Chatterjee S, Lalwani S, Ross C, Group T, Lin J, Luxembourg A, Walia A, Tu Y. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants. *Human Vaccines & Immunotherapeutics*. 2022 Nov 30;18(6):2105067.
10. Basu P, Muwonge R, **Bhatla N**, Nene BM, Joshi S, Esmey PO, Poli UR, Joshi G, Verma Y, Zomawia E, Shastri SS. Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years—updated evidence from Indian follow-up cohort study. *Papillomavirus research*. 2019 Jun 1;7:75-81